This benchmarking study assesses recent developments in biologics, including monoclonal antibodies and recombinant proteins, with a focus on the successes and challenges across the research & development spectrum. Building on prior rounds conducted over the prior five years, the study examines questions of investment, including licensing, along with productivity, cycle times and outcomes. At the same time, it examines the industry’s biologics readiness through study of capability, capacity and resources as well as the use of technology. An examination of acquisitions, partnering and outsourcing will also be explored to assess how companies are keeping pace with their growing biologic’s portfolios. In short, topics range from probability of success to manufacturing issues, with the intent of addressing the most pressing performance and business matters.